Document Detail


Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis.
MedLine Citation:
PMID:  9676791     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The primary objective of the Diabetes Atherosclerosis Intervention Study (DAIS) is to determine by quantitative coronary angiography whether long-term correction of the dyslipoproteinemia of diabetes with micronized fenofibrate results in evidence of decreased progression or regression of angiographically measured obstructive coronary atherosclerosis. The purpose of this communication is to describe the angiographic methodology for the DAIS project, and to present data documenting the reproducibility of measurements that will determine the primary outcome of DAIS. Four hundred eighteen subjects between the ages of 40 and 65 were entered from 11 centers in Canada, France, Finland, and Sweden, with 305 males and 113 females. Thirty-two percent of subjects had undergone a previous coronary artery intervention, either PTCA or bypass grafting. Subjects underwent coronary arteriography at baseline according to a strictly defined protocol. The coronary tree was divided into AHA segments and quantitative analysis of segments was performed using the cardiovascular measurement system described by Reiber. Geometric parameters including mean lumen diameter, minimum lumen diameter, maximum lumen diameter, and segment length were determined. In 15 studies, measurements were carried out on the same frame by two observers, and at least 1 week apart by the same observer. In 13 studies, measurements were performed by the same observer on two separate injections of the same coronary artery. The mean of the standard deviation of the differences of measurements of all segments for the primary study analyst was 0.029 mm, with a mean of correlation coefficients of 1.00. Between two observers, the mean of the standard deviations of segmental mean lumen diameters was 0.347 mm with a mean of coefficients of variation of 0.78. The mean of standard deviations for measurements of segmental mean lumen diameter from two separate coronary injections was 0.122, with a mean of correlation coefficients of 0.94. The mean of correlation coefficients for minimum lumen diameter were 0.98 for intraobserver variability, 0.77 for inter-observer variability, and 0.96 for inter-angiogram variability. For segment length the corresponding values were 0.99, 0.79, and 0.94. These data demonstrate that a high level of reproducibility and precision may be achieved in a multicenter study in assessment of the coronary tree in carefully performed studies using this methodology. We anticipate the results will provide a statistically powerful conclusion with new and unique data to answer the question of the effect of long-term correction of dyslipoproteinemia on coronary atherosclerosis in type II diabetic patients with dyslipoproteinemia.
Authors:
P R McLaughlin; P Gladstone
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Catheterization and cardiovascular diagnosis     Volume:  44     ISSN:  0098-6569     ISO Abbreviation:  Cathet Cardiovasc Diagn     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-09-25     Completed Date:  1998-09-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7508512     Medline TA:  Cathet Cardiovasc Diagn     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  249-56     Citation Subset:  IM    
Affiliation:
Core Angiographic Laboratory, World Health Organization Collaborating Center for the Study of Atherosclerosis in Diabetes, The University of Toronto and The Toronto Hospital, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antilipemic Agents / therapeutic use
Coronary Angiography*
Coronary Artery Disease / drug therapy,  radiography*
Diabetes Mellitus, Type 2*
Diabetic Angiopathies / drug therapy,  radiography*
Disease Progression
Humans
Middle Aged
Observer Variation
Procetofen / therapeutic use
Reproducibility of Results
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 49562-28-9/Procetofen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bilateral percutaneous balloon angioplasty of the axillary arteries in a patient with giant cell art...
Next Document:  Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary...